版本:
中国

BRIEF-FDA approves Tesaro's ovarian cancer drug

March 27 U.S. FDA:

* U.S. FDA granted the approval of Zejula to Tesaro Inc

* U.S. FDA - FDA granted the application fast track, priority review and breakthrough therapy designations

* U.S. FDA - Zejula also received orphan drug designation specifically for its use in treating recurrent epithelial ovarian cancer

* U.S. FDA approves maintenance treatment for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancers Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐